News Quantified

LFWD – lifeward ltd. - ordinary shares (US:NASDAQ)

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval

11/18

08:03 am

lfwd

Low

Lifeward (NASDAQ:LFWD) had its price target lowered by analysts at HC Wainwright from $13.00 to $4.50. They now have a "buy" rating on the stock.

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton

Lifeward Ltd. Reports Third Quarter 2025 Financial Results

Lifeward to Report Third Quarter Financial Results on November 14, 2025

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}